Cited by 924Acute Myeloid Leukemia ResearchChromatin Remodeling and CancerHematopoietic Stem Cell Transplantation

TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human Lymphomagenesis

Open access
Quivoron, Cyril, Couronné, Lucile, Della Valle, Véronique, Lopez, Cécile K., Plo, Isabelle, Wagner-Ballon, Orianne, Do Cruzeiro, Marcio, Delhommeau, Francois +15 more·2011·Cancer Cell

Abstract

Loss-of-function mutations affecting one or both copies of the Ten-Eleven-translocation (TET)2 gene have been described in various human myeloid malignancies. We report that inactivation of Tet2 in mouse perturbs both early and late steps of hematopoiesis including myeloid and lymphoid differentiation in a cell-autonomous manner, endows the cells with competitive advantage, and eventually leads to the development of malignancies. We subsequently observed TET2 mutations in human lymphoid disorders. TET2 mutations could be detected in immature progenitors endowed with myeloid colony-forming potential. Our results show that the mutations present in lymphoid tumor cells may occur at both early and later steps of lymphoid development and indicate that impairment of TET2 function or/and expression predisposes to the development of hematological malignancies.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2011.06.003

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tet2 loss of function in murine HSPCs leads to increased self-renewal and pool expansion, higher competitive repopulation capacity, and a predisposition to hematological malignancy development.

    “Indeed, Tet2 loss of function in murine HSPCs leads to increased self-renewal and pool expansion, higher competitive repopulation capacity, and a predisposition to hematological malignancy development.11, 12, 13”
  • In BM chimeras, Tet2+/− PB CD45.2+ cells show increased repopulating capacity compared with WT in the PBS groups.

    “As previously reported, we observed increased repopulating capacity in Tet2+/− PB CD45.2+ compared with WT in the PBS groups.11, 12, 13”
  • Higher basal level of self-renewal, repopulation capacity, and general fitness is reported in Tet2 loss-of-function HSPCs.

    “This likely results from a higher basal level of self-renewal, repopulation capacity, and general fitness reported in Tet2 loss-of-function HSPCs.11, 12, 13”
  • D-2-hydroxyglutarate (D2HG) inhibits numerous demethylases, leading to changes in genomic and transcriptomic methylation profiles as well as gene expression and genome topology.

    “D-2-hydroxyglutarate (D2HG) is one such oncometabolite, which inhibits numerous demethylases, leading to changes in genomic and transcriptomic methylation profiles as well as gene expression and genome topology 32,90-92 .”
  • This leads to significantly higher m6A levels in IDH1/2-mutant than in IDH1/2-wild-type AML, despite comparable FTO expression.

    “This leads to significantly higher m6A levels in IDH1/2-mutant than in IDH1/2-wild-type AML, despite comparable FTO expression 90 .”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Quivoron, C., Couronné, L., Della Valle, V., Lopez, C. K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., Godley, L., Opolon, P., Tilly, H., Solary, E., Duffourd, Y., Dessen, P., Merle-Beral, H., Nguyen-Khac, F., Fontenay, M., Vainchenker, W., Bastard, C., Mercher, T., & Bernard, O. A.
Affiliations
  • Université Paris-Sud (FR)
  • Hôpital Saint-Louis (FR)
  • Inserm (FR)
  • University of Chicago (US)
  • Institut Gustave Roussy (FR)
  • Centre National de la Recherche Scientifique (FR)
Corresponding author
Bernard, Olivier A.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2011-07
Volume
20
Issue
1
Pages
25-38
ISSN
1535-6108 (ISSN-L)
OpenAlex
W2028078153
Cited by
924
References
32
Citations by year
2026: 27 · 2025: 39 · 2024: 30 · 2023: 52 · 2022: 53 · 2021: 81 · 2020: 66 · 2019: 53 · 2018: 59 · 2017: 69 · 2016: 75 · 2015: 75 · 2014: 82 · 2013: 66 · 2012: 68
FWCI
53.43
Type
journal article
Language
en
Update notices
erratum (2011-08-16)
Open access
Locations
  • Cancer Cell (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Ligue Contre le Cancer
  • Institut National Du Cancer
  • Fondation Gustave Roussy
  • École des Neurosciences Paris Île de France
  • Institut National de la Santé et de la Recherche Médicale
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
Keywords
TET2, hematopoiesis, lymphoid differentiation, myeloid differentiation, lymphomagenesis, loss-of-function mutations, hematologic malignancies, myeloid progenitor cells, competitive advantage, mouse model
MeSH terms
Animals, DNA-Binding Proteins, Hematopoiesis, Hematopoietic Stem Cells, Homeostasis, Humans, Lymphoma, Mutation, Precancerous Conditions, Proto-Oncogene Proteins, Antigens, CD34, Cell Lineage, Gene Silencing, Myeloid Cells, Models, Animal, Dioxygenases, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review